Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of T-Guard vs ruxolitinib in steroid-refractory acute graft-versus-host disease
2021-000343-53Phase 3Terminated
- Sponsor
- Xenikos
- Start
- Jul 2021
- Modality
- Small Molecules, Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Acute Graft-Versus-Host Disease (aGvHD) comparing T-Guard with Ruxolitinib (2 arms). Primary endpoint: Complete response at Day 28. Started Jul 2021; status: terminated.
02
Drugs
T-Guardruxolitinib
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on 2021-000343-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000343-53.